Anti-interleukin-12 antibody: potential role in preventing relapses of multiple sclerosis.

Journal: BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals And Gene Therapy
Published:
Abstract

Multiple sclerosis is an inflammatory demyelinating disorder of the central nervous system. Immunological evidence from patients with multiple sclerosis and experimental models suggests that the cytokine interleukin-12 (IL-12) plays an important role in the pathogenesis of inflammatory demyelination. In experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis, antibodies that block IL-12 can prevent relapses of the disease. Anti-IL-12 antibodies present a novel approach for preventing relapses in multiple sclerosis.

Authors
R Fox, A Rostami